Assessment of placental protein 13 as a new marker for early diagnosis of preeclampsia | ||
| Journal of Current Medical Research and Practice | ||
| Volume 6, Issue 4, October 2021, Pages 399-404 PDF (362.4 K) | ||
| DOI: 10.4103/jcmrp.jcmrp_129_20 | ||
| Authors | ||
| Marwa M. H. Mohamed; Lubna M. T. El-Din; Dalia A. A. E. Nigm; Tarek A. Farghaly | ||
| Abstract | ||
| Background Preeclampsia is an important cause of maternal and perinatal morbidity and mortality, affecting 2–8% of pregnancies worldwide. Aim The study aimed to examine the potential value of maternal serum concentration of placental protein 13 (PP13) in early diagnosis of preeclampsia (11–13 weeks of gestation). Patients and methods This study was carried out on 120 pregnant women at risk for preeclampsia (60 women with advanced maternal age >35 years, and 60 women with a history of chronic hypertension, diabetes, kidney disease, and systemic lupus erythematosus) and 40 women apparently healthy as controls. Serum PP13 was measured by the enzyme-linked immunosorbent assay kits from SinoGeneClon Biotech Co. Ltd, catalog number: SG-10912. Patients signed an informed consent form. Assiut Faculty of Medicine approved The study was approved by the Ethical Committee of Faculty of Medicine Assiut University, with registration number IRB: 17101046. Results PP13 was significantly decreased in pregnant women with risk factors for preeclampsia (women with advanced maternal age > 35 years, as well as women with a history of chronic hypertension, diabetes, kidney disease, and systemic lupus erythematosus) compared with the control group. Conclusion This study has revealed that serum levels of PP13 can be used as a predictive test in preeclampsia. | ||
| Keywords | ||
| placental protein 13; preeclampsia; enzyme-linked immunosorbent assay technique | ||
|
Statistics Article View: 12 PDF Download: 15 |
||
